Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Iraq Healthcare Wire.
Press releases published on September 17, 2025
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today …
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners …
National Association of Specialty Pharmacy Honors Poster Award Winners and Scholarship Recipients at the 2025 Annual Meeting & Expo
Washington, DC, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) recognized outstanding poster presentations and awarded five Ron Bookman Memorial Scholarships during its record-breaking 2025 Annual Meeting …
Digital Utilities Ventures Provides Corporate Update
MANKATO, Minn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Digital Utilities Ventures, Inc. (OTC: DUTV), soon to be operating as Easy Environmental Solutions, today issued a corporate update highlighting recent developments across acquisitions, international …
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
MALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and …
iPETcertum™ by Claritas, State-of-the-Art Software for Enhancement, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives Clearance from Brazilian Regulator ANVISA
NEW YORK and LONDON and SAO PAULO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed Brazil”), a subsidiary of UK-based Claritas NucMed Technologies Ltd (“Claritas NucMed”), a company specializing in image processing and …
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented at the inaugural …
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s new Orion® …
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary …
Safety Shot Announces Strategic Board Refresh to Align with New Corporate Vision
Company Appoints New Directors with Deep Expertise in Venture Capital, Financial Due Diligence, and Bitcoin Mining to Guide Next Phase of Growth SCOTTSDALE, AZ, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced a strategic …
CDT Executes Cryptocurrency Treasury Reserve Strategy
NAPLES, Fla. And CAMBRIDGE, United Kingdom, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced the strategic acquisition of 8.65252366 Bitcoin (“BTC”) for an aggregate purchase price of $1,000,000 ( …
Intelligent Bio Solutions Provides Update on FDA 510(k) Clearance Process for Intelligent Fingerprinting Drug Screening System
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided an update on its FDA 510(k) …
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Phonak ambassador, Rylee Foster, kicks down barriers by becoming the first soccer player with hearing loss to play for a division 1 league in the US
STÄFA, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- This past year, professional soccer player Rylee Foster has been serving as a Brand Ambassador and Hearing Health Champion for Phonak, a global leader in hearing care solutions. In this role, Rylee is …
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors
KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board …
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapy Robust mKRAS-specific T cell responses were observed with an average of 145.3x increase over baseline ( …
Rgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC)
WOBURN, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, …
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation - Preclinical data demonstrating potential efficacy of CD388 to prevent H5N1 infection featured in …